acetaldehyde has been researched along with Fanconi Anemia in 19 studies
Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.
acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.
aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.
acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.
Fanconi Anemia: Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fanconi anemia is a genetic bone marrow failure syndrome." | 5.42 | The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. ( Deater, M; Grompe, M; Marquez-Loza, L; Pelz, C; Schubert, K; Sinclair, DA; Zhang, QS, 2015) |
| "Fanconi anemia is a genetic bone marrow failure syndrome." | 1.42 | The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. ( Deater, M; Grompe, M; Marquez-Loza, L; Pelz, C; Schubert, K; Sinclair, DA; Zhang, QS, 2015) |
| "Fanconi anemia is characterized by a higher sensitivity to DNA crosslinking agents, including aldehydes." | 1.40 | The maternal side of Fanconi Anemia. ( Fernandez-Capetillo, O; Ruiz, S, 2014) |
| "Since the Fanconi anemia-breast cancer associated (FANC-BRCA) DNA damage response network plays a crucial role in protecting cells against ICLs, in the present work we tested this hypothesis by exposing cells to AA and monitoring activation of this network." | 1.35 | Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis. ( Brooks, PJ; Lamerdin, JE; Marietta, C; Thompson, LH, 2009) |
| "Formaldehyde is an aliphatic monoaldehyde and is a highly reactive environmental human carcinogen." | 1.34 | Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde. ( Arakawa, H; Bishop, DK; Buerstedde, JM; Gillespie, DA; Luke, AM; Nakamura, A; Nakamura, J; Ridpath, JR; Sale, JE; Sonoda, E; Swenberg, JA; Takata, M; Takeda, S; Tano, K; Watanabe, M; Yamazoe, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Peake, JD | 2 |
| Horne, KI | 1 |
| Noguchi, C | 3 |
| Gilligan, JP | 1 |
| Noguchi, E | 3 |
| Hodskinson, MR | 1 |
| Bolner, A | 1 |
| Sato, K | 1 |
| Kamimae-Lanning, AN | 1 |
| Rooijers, K | 1 |
| Witte, M | 1 |
| Mahesh, M | 1 |
| Silhan, J | 1 |
| Petek, M | 1 |
| Williams, DM | 1 |
| Kind, J | 1 |
| Chin, JW | 1 |
| Patel, KJ | 5 |
| Knipscheer, P | 1 |
| Rogers, CM | 1 |
| Simmons Iii, RH | 1 |
| Fluhler Thornburg, GE | 1 |
| Buehler, NJ | 1 |
| Bochman, ML | 1 |
| Semlow, DR | 1 |
| Walter, JC | 1 |
| Lin, B | 1 |
| Theriault, A | 1 |
| O'Connor, M | 1 |
| Sheth, S | 1 |
| Tanaka, K | 2 |
| Nakagawa, H | 2 |
| Garaycoechea, JI | 2 |
| Crossan, GP | 4 |
| Langevin, F | 4 |
| Mulderrig, L | 1 |
| Louzada, S | 1 |
| Yang, F | 1 |
| Guilbaud, G | 1 |
| Park, N | 1 |
| Roerink, S | 1 |
| Nik-Zainal, S | 1 |
| Stratton, MR | 1 |
| Ghosh, S | 1 |
| Sur, S | 1 |
| Yerram, SR | 1 |
| Rago, C | 1 |
| Bhunia, AK | 1 |
| Hossain, MZ | 1 |
| Paun, BC | 1 |
| Ren, YR | 1 |
| Iacobuzio-Donahue, CA | 1 |
| Azad, NA | 1 |
| Kern, SE | 1 |
| Oberbeck, N | 1 |
| King, G | 1 |
| de Wind, N | 1 |
| Delan-Forino, C | 1 |
| Tollervey, D | 1 |
| Ruiz, S | 1 |
| Fernandez-Capetillo, O | 1 |
| Zhang, QS | 1 |
| Deater, M | 1 |
| Schubert, K | 1 |
| Marquez-Loza, L | 1 |
| Pelz, C | 1 |
| Sinclair, DA | 1 |
| Grompe, M | 2 |
| Zhang, H | 1 |
| Kozono, DE | 1 |
| O'Connor, KW | 1 |
| Vidal-Cardenas, S | 1 |
| Rousseau, A | 1 |
| Hamilton, A | 1 |
| Moreau, L | 1 |
| Gaudiano, EF | 1 |
| Greenberger, J | 1 |
| Bagby, G | 1 |
| Soulier, J | 1 |
| Parmar, K | 1 |
| D'Andrea, AD | 1 |
| Grothusen, G | 1 |
| Anandarajan, V | 1 |
| Martínez-Lage García, M | 1 |
| Terlecky, D | 1 |
| Corzo, K | 1 |
| Brooks, PJ | 2 |
| Schuebel, K | 1 |
| Marietta, C | 1 |
| Thompson, LH | 1 |
| Lamerdin, JE | 1 |
| Joenje, H | 1 |
| Rosado, IV | 1 |
| Arends, MJ | 2 |
| Daly, M | 1 |
| Ridpath, JR | 1 |
| Nakamura, A | 1 |
| Tano, K | 1 |
| Luke, AM | 1 |
| Sonoda, E | 1 |
| Arakawa, H | 1 |
| Buerstedde, JM | 1 |
| Gillespie, DA | 1 |
| Sale, JE | 1 |
| Yamazoe, M | 1 |
| Bishop, DK | 1 |
| Takata, M | 1 |
| Takeda, S | 1 |
| Watanabe, M | 1 |
| Swenberg, JA | 1 |
| Nakamura, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)[NCT04103645] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-11-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for acetaldehyde and Fanconi Anemia
| Article | Year |
|---|---|
Fanconi anemia-independent DNA inter-strand crosslink repair in eukaryotes.
Topics: Acetaldehyde; Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cross-Linking Reagents; DNA | 2020 |
Mechanisms of Vertebrate DNA Interstrand Cross-Link Repair.
Topics: Acetaldehyde; Animals; DNA; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Damage; DN | 2021 |
17 other studies available for acetaldehyde and Fanconi Anemia
| Article | Year |
|---|---|
The p53 DNA damage response and Fanconi anemia DNA repair pathway protect against acetaldehyde-induced replication stress in esophageal keratinocytes.
Topics: Acetaldehyde; DNA Damage; DNA Repair; DNA Replication; Esophagus; Ethanol; Fanconi Anemia; Genomic I | 2023 |
Alcohol-derived DNA crosslinks are repaired by two distinct mechanisms.
Topics: Acetaldehyde; Animals; Cisplatin; Cross-Linking Reagents; DNA; DNA Damage; DNA Repair; DNA Replicati | 2020 |
FANCD2 limits acetaldehyde-induced genomic instability during DNA replication in esophageal keratinocytes.
Topics: Acetaldehyde; DNA Damage; DNA Repair; DNA Replication; Esophagus; Fanconi Anemia; Fanconi Anemia Com | 2021 |
Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells.
Topics: Acetaldehyde; Alcohol Dehydrogenase; Animals; Cell Survival; DNA Breaks, Double-Stranded; DNA End-Jo | 2018 |
Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genes.
Topics: Acetaldehyde; Animals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Fanconi Anemi | 2014 |
Maternal aldehyde elimination during pregnancy preserves the fetal genome.
Topics: Acetaldehyde; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Dehydrogenase, Mitoc | 2014 |
Lighting Up pre-mRNA recognition.
Topics: Acetaldehyde; Aldehyde Dehydrogenase; Animals; Embryo, Mammalian; Ethanol; Fanconi Anemia; Fanconi A | 2014 |
The maternal side of Fanconi Anemia.
Topics: Acetaldehyde; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Animals; Embryo, Mammal | 2014 |
The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice.
Topics: Acetaldehyde; Anilides; Animals; Blood Cell Count; Cell Proliferation; Diet; Ethanol; Fanconi Anemia | 2015 |
TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia.
Topics: Acetaldehyde; Animals; Bone Marrow; Cell Survival; DNA End-Joining Repair; Down-Regulation; Fanconi | 2016 |
Genetic controls of DNA damage avoidance in response to acetaldehyde in fission yeast.
Topics: Acetaldehyde; Adaptation, Physiological; Cell Cycle Checkpoints; DNA Adducts; DNA Damage; DNA Repair | 2017 |
Timeless insights into prevention of acetaldehyde genotoxicity?
Topics: Acetaldehyde; DNA Damage; DNA Repair; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protei | 2017 |
Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis.
Topics: Acetaldehyde; Alcohol Drinking; BRCA1 Protein; Cell Line; Cross-Linking Reagents; DNA Damage; Ethano | 2009 |
Metabolism: alcohol, DNA and disease.
Topics: Acetaldehyde; Alcohol Drinking; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Anima | 2011 |
Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice.
Topics: Acetaldehyde; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Aldehydes; Alleles; Ani | 2011 |
Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function.
Topics: Acetaldehyde; Aging; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Aldehydes; Anima | 2012 |
Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde.
Topics: Acetaldehyde; Acrolein; Aldehydes; Animals; BRCA1 Protein; Cell Cycle; Cell Survival; Chickens; Cros | 2007 |